FDMT vs. SION, GYRE, PHAT, ANAB, IMTX, TRVI, NUVB, DAWN, GHRS, and STOK
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Sionna Therapeutics (SION), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), AnaptysBio (ANAB), Immatics (IMTX), Trevi Therapeutics (TRVI), Nuvation Bio (NUVB), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry.
4D Molecular Therapeutics vs. Its Competitors
4D Molecular Therapeutics (NASDAQ:FDMT) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.
4D Molecular Therapeutics presently has a consensus price target of $29.56, suggesting a potential upside of 648.24%. Sionna Therapeutics has a consensus price target of $38.50, suggesting a potential upside of 83.68%. Given 4D Molecular Therapeutics' higher probable upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than Sionna Therapeutics.
Sionna Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. Sionna Therapeutics' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.
Sionna Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 3.9% of Sionna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 8 mentions for 4D Molecular Therapeutics and 5 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 1.15 beat 4D Molecular Therapeutics' score of 0.06 indicating that Sionna Therapeutics is being referred to more favorably in the news media.
Summary
4D Molecular Therapeutics and Sionna Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FDMT) was last updated on 7/8/2025 by MarketBeat.com Staff
Free FDMT Stock Alerts